Back to search results

Study of INCA33890 for Advanced Solid Tumors

This study is testing a drug called INCA33890 in people with advanced or metastatic (spread to other parts of the body) solid tumors. Researchers want to understand how safe INCA33890 is and what side effects it might cause, especially when given alone or with other common cancer treatments like bevacizumab, FOLFIRI, FOLFOX, or Cetuximab. You might be able to join if you are at least 18 years old and your cancer has progressed after other treatments, or if you can't take or refused other available therapies. The main goal is to find the safest dose of INCA33890. This study is currently recruiting 570 participants.

Study design
This is an interventional study designed to evaluate the safety and tolerability of INCA33890. It plans to enroll 570 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be monitored for treatment-emerging adverse events (side effects) for up to 2 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05836324

A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

Recruiting
PHASE1Ages 18+InterventionalTreatment
Incyte Corporation
~570 participants
Updated 2026-07-23 on ClinicalTrials.gov
What's tested:INCA33890bevacizumabFOLFIRIFOLFOXCetuximabADG126

At a glance

Recruiting sites
36 of 39 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Dose Limiting Toxicities (DLTs)
Measured over Up to 28 days
+2 more outcomes measured

Conditions

Solid Tumors
Advanced Solid Tumors
Metastatic Solid Tumors

Explore related trials

Solid Neoplasm

NCT05836324

Where you'd take part

This study runs at 39 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Cambridge University Hospitals Nhs Foundation Trust

    Cambridge, United Kingdomno site contact published

    Recruiting

  • Cancer and Hematology Centers of Western Michigan-Start Midwest

    Grand Rapids, Michiganno site contact published

    Recruiting

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Chinano site contact published

    Not yet recruiting

  • Centre Hospitalier Universitaire Vaudois (Chuv)

    Lausanne, Switzerlandno site contact published

    Recruiting

  • Centre Leon Berard

    Lyon, Franceno site contact published

    Recruiting

  • Centro Integral Oncologico Clara Campal

    Madrid, Spainno site contact published

    Recruiting

  • Centro Ricerche Cliniche Di Verona

    Verona, Italyno site contact published

    Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusettsno site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Incyte Corporation Call Center (US)
[email protected]
1.855.463.3463
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

≥18 years old
Histologically or cytologically confirmed advanced or metastatic malignancies as defined in the protocol.
Part 1: Participants must have experienced disease progression after treatment with, be intolerant to, or be ineligible for, or refused available therapies, including anti-PD-(L)1 or anti-CTLA4 therapy if applicable, that are known to confer clinical benefit. Part 2: depending on cohort, participants may have received or not prior treatment for the malignancy under study.
ECOG performance status score of 0 or 1.
Willingness to undergo pre- and on-treatment tumor biopsy (core or excisional). Biopsies are mandatory depending on the cohorts.
Presence of measurable disease according to RECIST v1.1.

Exclusion

Any known additional malignancy that is progressing or requires active treatment, or history of other malignancy within 2 years.
Not recovered to ≤ Grade 1 or baseline from residual toxicities of prior therapy.
Has active autoimmune disease requiring systemic immunosuppression with corticosteroids.
Brain or CNS metastases untreated or that have progressed.
History of organ transplant, including allogeneic stem cell transplantation.
History of clinically significant or uncontrolled cardiac disease.
Active HBV, active HCV, or HIV positive.
Is on chronic systemic steroids (\> 10 mg/day of prednisone or equivalent).
Chronic or current active infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment
Participants that have been initiated on or had modifications in anticoagulation therapies within the last 3 months prior to first dose of treatment.
Significant concurrent, uncontrolled medical condition, eg:
Cardiovascular: Participants with known vasculitis, aneurisms, and other vascular malformations of clinical significance or history of myocarditis.
Gastrointestinal: Any bowel obstruction within 60 days prior to C1D1.
Participants with adequate laboratory values within the protocol defined ranges.

What this trial measures

  • Dose Limiting Toxicities (DLTs)Up to 28 days
  • Treatment Emerging Adverse Events (TEAEs)Up to 2 years
  • TEAEs leading to dose modification or discontinuationUp to 2 years